Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Silo Pharma Inc
(NQ:
SILO
)
0.9800
-0.0083 (-0.84%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Silo Pharma Inc
< Previous
1
2
3
4
5
Next >
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030
December 30, 2022
EQNX::TICKER_START (NASDAQ:SILO),(NASDAQ:BXRX),(NASDAQ:HOTH),(NASDAQ:KALA),(NASDAQ:NUWE) EQNX::TICKER_END
Via
FinancialNewsMedia
Silo Pharma Announces Positive Study Results of SPU
December 30, 2022
21 for Arthritis – SPU-21 effective in controlling arthritis progression SPU-21 Demonstrates Positive Data in Arthritis Suppression using Silo’s Novel Joint Homing Peptide Englewood Cliffs, – December...
Via
FinancialNewsMedia
Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis
December 30, 2022
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) CEO Discusses Advancement of Pipeline, Positioning in Shareholder Letter
December 01, 2022
Via
Investor Brand Network
Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine
December 01, 2022
From
Silo Pharma, Inc.
Via
GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advancing Research of SPU-21 in Human Synovial Tissue
November 21, 2022
Via
Investor Brand Network
Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
November 21, 2022
From
Silo Pharma, Inc.
Via
GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Milestone in IND-Enabling Study of Time-Released Ketamine Formulation
November 11, 2022
Via
Investor Brand Network
Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation
November 11, 2022
From
Silo Pharma, Inc.
Via
GlobeNewswire
New Psychedelic Journal to Focus on Publishing Psychedelic Research
November 07, 2022
Via
Investor Brand Network
Silo Pharma Inc. (NASDAQ: SILO) Extends Columbia University Agreement to Continue Research for Therapeutics to Treat Alzheimer’s Disease
November 04, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Confident in Preclinical Work on Its Novel Ketamine Formulation
November 03, 2022
Via
Investor Brand Network
Microscopy Provides Insights on Psychedelics Action Inside Neuropathways
October 28, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Present at Largest Gathering in Psychedelic Medicine Sector
October 26, 2022
Via
Investor Brand Network
Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference
October 26, 2022
From
Silo Pharma, Inc.
Via
GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Distinctive with Ground-Breaking Research, Commitment to Developing Innovative Solutions
October 24, 2022
Via
Investor Brand Network
What You Should Know About Colorado’s Psychedelics Ballot Measure
October 24, 2022
Via
Investor Brand Network
Silo Pharma Inc.’s (NASDAQ: SILO) Novel Ketamine Formulation Undergoing Safety Evaluation, Pursuing Regulatory Pathway
October 24, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Data Supporting SPC-14’s Therapeutic Potential for Alzheimer’s
October 20, 2022
Via
Investor Brand Network
Exposures
Product Safety
Alzheimer’s Pipeline of New Treatments Race to Improve Quality of Life for Patients
October 20, 2022
Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which...
Via
FinancialNewsMedia
Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study
October 20, 2022
Dosing study of SPC-14 demonstrates efficacy for increasing memory function Englewood Cliffs, NJ – October 20, 2022 – Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage...
Via
FinancialNewsMedia
Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study
October 20, 2022
Dosing study of SPC-14 demonstrates efficacy for increasing memory function
From
Silo Pharma, Inc.
Via
GlobeNewswire
Florida Dispensary Uncovers Legal Loophole, Starts Selling Shrooms
October 18, 2022
Via
Investor Brand Network
Topics
Law Enforcement
Exposures
Legal
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Agreement with Columbia University to Extent Research Pact
October 18, 2022
Via
Investor Brand Network
Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety Therapeutics
October 18, 2022
Silo and Columbia University continue research on SPC-14 for Alzheimer’s and SPC-15 for Stress Induced Disorders
From
Silo Pharma, Inc.
Via
GlobeNewswire
Silo Pharma Stock Higher After Investors Appraise Innovative Treatment For Nerve Pain And Neurological Disorders ($SILO)
October 13, 2022
Via
AB Newswire
Exposures
Product Safety
Legislators in New York File Revised Measure to Legalize Psychedelics
October 12, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Initiates Safety Evaluation Study of Its Novel Time-Released Ketamine Formulation
October 10, 2022
Via
Investor Brand Network
Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia
October 10, 2022
From
Silo Pharma, Inc.
Via
GlobeNewswire
Silo Pharma’s Mission To Merge Traditional Pharmaceuticals With Psychedelic Compounds Can Be A Treatment Game-Changer For Neurological Disorders ($SILO)
October 10, 2022
Via
AB Newswire
Exposures
Product Safety
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.